Part of UT Health San Antonio

Part of UT Health San Antonio

You are here

John Sarantopoulos | UT Health San Antonio

Contact

210-450-1000

sarantopoulo@uthscsa.edu

Departments & Divisions

Institutes & Centers

Research

Research profile

John Sarantopoulos, MD

Associate Professor

Peggy & Lowry Mays Distinguished Chair Hematology Oncology

Dr. John Sarantopoulos is a clinical research investigator and medical oncologist, with a full-time faculty appointment as assistant professor of medicine in the division of hematology-oncology at UT Health San Antonio. His clinical interests and expertise are in early antineoplastic drug development and evaluation for human solid tumors including genitourinary malignancies of renal, prostate, bladder and melanoma. He is involved with the Cancer Therapy & Research Center’s early therapeutics phase I program, and is a member of the experimental developmental therapeutics program.

Dr. Sarantopoulos completed an advance drug development fellowship and is presently focusing on early phase I/II trials. He has been a co-principal investigator and principal investigator in over 54, phase I solid tumor studies, including first in human studies or first in class compounds, food effect or bioequivalence studies, drug interaction studies, QTc effect studies, and organ dysfunction studies, including renal and hepatic impairment. Studies have included National Cancer Institute cancer therapy evaluation program studies and the NCI organ dysfunction working group and cooperative group trials including the Southwest Oncology Group, where he is a member of the early therapeutics and genitourinary committees, as well as industry-sponsored and cancer center investigator-initiated trials.

In addition, he has been a sub investigator in over 139 trials in this area at the CTRC over the last several years. Dr. Sarantopoulos’ education, clinical and research experiences place him in a select group of investigators that can complete complex early phase trials that are important to the development of new treatments for patients with cancer.

Publications

Curtis, K. K., Sarantopoulos, J., Northfelt, D. W., Weiss, G. J., Barnhart, K. M., Whisnant, J. K., Leuschner, C., Alila, H., Borad, M. J. & Ramanathan, R. K. Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors. Cancer Chemother. Pharmacol. 73(5):931-41 (2014). PMID: 24610297; PMCID: PMC4000412

Falchook, G. S., Venkatakrishnan, K., Sarantopoulos, J., Kurzrock, R., Mita, A. C., Fu, S., Mita, M. M., Zhou, X., Jung, J. A., Ullmann, C. D., Milch, C. & Rosen, L. S. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. Int. J. Clin. Pharmacol. Ther. 53, 563-572 (2015). PMID: 26073352

Kurzrock, R., Gabrail, N., Chandhasin, C., Moulder, S., Smith, C., Brenner, A., Sankhala, K., Mita, A., Elian, K., Bouchard, D. & Sarantopoulos, J.  Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Molecular Cancer Therapeutics 11(2):308-16. doi: 10.1158/1535-7163.MCT-11-0566 (2012). PMID:22203732

  • Professional Background

    Education

    • 2006 - Clinical Fellowship - Advanced Oncology Drug Development Fellowship - Institute for Drug Development, Cancer Therapy & Research Center
    • 2003 - Clinical Fellowship - Medical Oncology (Chief Resident 09/2001 - 01/2003) - University of Calgary - Tom Baker Cancer Centre
    • 2003 - Clinical Fellowship - Medical Oncology, Hematology, Bone Marrow Transp - Tom Baker Cancer Centre - Foothills Hospital, Calgary Health Region
    • 2003 - Clinical Fellowship - Chief Medical Oncology Fellow - University of Calgary - Tom Baker Cancer Centre
    • 2000 - Residency - Internal Medicine - University of Calgary - Foothills Hospital
    • 1997 - MD - Medicine - University of Manitoba, Faculty of Medicine
    • 1992 - BS - Chemistry/Microbiology (Dean`s Honour List 1989-1992) - University of Manitoba, Faculty of Science

    Appointments

    • 9/2015 - Interim Director - Institute for Drug Development CTRC/UT Health Science Center at San Antonio, Medicine, San Antonio
    • 9/2015 - Associate Professor - University of Texas Health Science Center San Antonio, Cancer Therapy and Research Center, Medicine, San Antonio
    • 5/2011 - Leader Phase I Experimental Therapeutics - University of Texas Health Science Center San Antonio, Cancer Therapy and Research Center, Medicine, San Antonio
    • 1/2011 - Leader Melanoma Program - CTRC/IDD/UT Health Science Center at San Antonio, Medicine, San Antonio
    • 1/2011 - Co-Leader Genitourinary Program - CTRC/IDD/UT Health Science Center at San Antonio, Medicine, San Antonio
    • 1/2011 - Leader Phase I Experimental Therapeutics - CTRC/IDD/UT Health Science Center at San Antonio, Medicine, San Antonio

  • Instruction & Training

    • 2/2013 - Present, Phase I Drug Development Journal Club, Cancer Therapy and Research Center at University of Texas Health Science Center at San Antonio
    • 5/2012 - Present, Cancer Cell Biology, The University of Texas Health Science Center
    • 3/2012 - Present, Patient Orient Clin Res Method-2, The University of Texas Health Science Center
    • 9/2011 - Present, Drug Development Lecture Series, Cancer Therapy and Research Center at University of Texas Health Science Center at San Antonio
    • 12/2009 - Present, GU Journal Club, Cancer Therapy and Research Center at University of Texas Health Science Center at San Antonio
    • 12/2007 - Present, Medical students, residents and oncology fellows, University of Texas Health Science Center at San Antonio
    • 12/2007 - Present, Medical Oncology Journal Club, Cancer Therapy and Research Center at University of Texas Health Science Center at San Antonio
    • 12/2007 - Present, Post Graduate Rotation Supervision, University of Texas Health Science Center at San Antonio
    • 12/2007 - Present, Post Graduate Rotation Supervision, University of Texas Health Science Center at San Antonio
    • 12/2007 - Present, Post Graduate Rotation Supervision, University of Texas Health Science Center at San Antonio

  • Research & Grants

    Clinical Trials, Lymphoma, Sarcoma

    Experimental and Developmental Therapeutics Program 

    Research profile

    Grants

    Private

    Funding Agency Novartis Title A Phase I/II, Open-Label, randomized, three arms, dose escalation trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of RAF265 (CHIR-265) administered orally to patients with locally advanced or metastatic melanoma Status Complete Period 3/2009 - Present Role Principal Investigator Grant Detail A Phase I/II, Open-Label, randomized, three arms, dose escalation trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of RAF265 (CHIR-265) administered orally to patients with locally advanced or metastatic melanoma.

  • Publications

      Abstract

      Sarantopoulos J, Dang L, Lauer R, Starodub A, Hauke R, Galsky M, Bylow K, Cowey C,
      Bibby D, Kremmidiotis G, Doolin E, Lavranos T, Iglesias J, Sonpavde G, Logan T, Hahn N,
      Sweeney C, Hutson T.
      . A phase I/II trial of BNC105P with Everolimus in metastatic renal cell carcinoma patients: Updated phase I results of the Disruptor-1 trial; 2013 Jan. (Journal Clinical Oncology 31:xxs ASCO 2013). Hutson T, Dang L, Lauer R, Starodub A, Hauke R, Galsky M, Bylow K, Cowey C, Bibby D,Kremmidiotis G, Doolin E, Lavranos T, Sonpavde G, Leske A, Logan T, Hahn N, Sweeney C, Sarantopoulos J. Updated phase I results of a phase I/II trial of BNC105P with everolimus in patients with metastatic renal cell carcinoma; 2013 Jan. (Journal Clinical Oncology 31:6s ASCO Genitourinary Symposium 2013). Rixe O, Sarantopoulos J, Hsueh C, Lockhart A, Ross S, Agarwala S, Zhang W, Yin J, Wack C, Mazur F, Gurtler J. Absence of interaction of cabazitaxel on the pharmacokinetics of midazolam: results of a drug-drug interaction study in patients with advanced solid tumor; 2013 Jan. (Journal Clinical Oncology 31:6s ASCO Genitourinary Symposium 2013). Mita M, Mahalingam D, Sarantopoulos J, Amaravadi R, Mita A, Curiel T, Nawrocki S, Giles F,
      Carew J.
      . A phase I dose escalation study to establish the maximum tolerated dose, pharmacokinetic and pharmacodynamic parameters of Hydroxychloroquine in combination with the Vorinostat, in patients with advanced solid tumors- final results; 2013 Jan. (Proc AACR 2013). Mita AC, Lockhart A, Wade J, Morris J, Rixe O, Dedieu JF, Wack C, Kassalow L,Sarantopoulos J. Phase I study of Cabazitaxel plus cisplatin in patients with advanced solid tumors: Substudy to evaluate the impact of a strong CYP3A inhibitor(ketoconazole) or inducer (rifampicin) on the pharmacokinetics of cabazitaxel; 2013 Jan. (Journal Clinical Oncology 31:xxs ASCO 2013). Mahalingam D, Shaheen M, Sarantopoulos J, Weitman S, Giovanella B, Cao Z, Coil D,
      Markides C, Liu L, Verschraegen C. A first in human phase I study of CZ48, a lactone ring protected oral camptothecin, in patients with advanced solid tumors; 2013 Jan. (Journal Clinical Oncology 31:xxs ASCO 2013). Mahalingam D, Wang Y, Lu TW, Sarantopoulos J, Vemulapalli S, Aparo S, Coffey M, Gill G,
      Kennealey G, Mita M. A Study of REOLYSIN in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma; 2012 Nov. (Proc 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Nov 2012). Sarantopoulos J, Chiorean EG, Stephenson J, Burris H, Mahalingam D, Younger A, Ayan-
      Oshodi M, Baldwin J, Infante. Pharmacokinetic Study of Enzastaurin in Cancer Patients with Varying Degrees of Hepatic Dysfunction; 2012 Nov. (Proc 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics). Mahalingam D, Mita M, Sarantopoulos J, Amaravadi R, Davis L, Mita A, Curiel T, Nawrocki
      S, Giles F, Carew J. Inhibition of Autophagy: a phase I safety, tolerability, pharmacokinetic and pharmacodynamic analysis of Hydroxychloroquine in combination with the HDAC inhibitor, Vorinostat, in patients with advanced solid tumors; 2012 Nov. (Proc 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics). Weitman S, Sarantopoulos J, Mahalingam D, Sankhala K, Brenner A, Kelly K, Ramirez A. Overcoming the barriers to early phase clinical trials (EPCT): Increasing EPCT minority accrual; 2012 Nov. (Submitted Proc 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapuetics Nov 2012). Mahalingam D, Wilding G, Denmeade S,
      Sarantopoulas J sp,Cosgrove D, Cetnar J, Azad N,
      Bruce J, Kurman M, Carducci M.
      . A first-in-human, phase 1 clinical study of the safety,tolerability and pharmacokinetics of G-202, a Thapsigargin-based PSMA-activated prodrug,in patients with advanced solid tumors; 2012 Nov. (Proc 24th EORTC-NCI-AACR Symposium on Molecular). Rowe J, Patel S, Mazo-Canola M, Parra A, Kelly K, Weitman S, Karnad A. Evaluation of Elderly Patients (>70 Years Old) Enrolled in Phase I Clinical Trials at University of Texas Health Science Center at San Antonio-Cancer Therapy Research Center From 2009-2011; 2012 Nov. (Proc 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics). Falchook G, Zhou X, Rosen L, Venkatakrishnan K, Kurzrock, R, Mahalingam D, Goldman J,
      Jung J, Milch C, Sarantopoulos J. Food Effect Study of the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib) in Patients with Advanced Solid Tumors; 2012 Sep. (ESMO 2012, Annals of Oncology; vol. 23). Hahn N, Sarantopoulos J, Higano C, Zhou X, Zhang B, Leonard EJ, Benaim E, Graff J. MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with advanced solid tumors including castration-resistant prostate cancer receiving a standard docetaxel regimen: Preliminary phase 1 results; 2012 Sep. (ESMO 2012, Annals of Oncology; vol. 2). Mahalingam D, Moseley J, Coffey M, Gill G, Nawrocki S, Pollock B, Sarantopoulos J. Phase 2 study of intravenous administration of reovirus in combination with paclitaxel and carboplatin in patients with advance metastatic melanoma; 2012 Jan. (Submitted TPS ASCO 2012). Hutson T, Dang L, Lauer R, Starodub A, Hauke R, Logan T, Bylow K, Galsky M, Bibby D, Kremmidiotis G, Doolin E, Lavranos T, Leske A, Hahn N, Sonpavde G, Sweeney C,
      Sarantopoulos J.
      . Phase I/II study of a BNC105P / everolimus regimen for progressive metastatic renal cell carcinoma following prior tyrosine kinase inhibitors; 2012 Jan. (Journal Clinical Oncology 30:5s ASCO Genitourinary Symposium). Lockhart A, Sundaram S, Sarantopoulos J, Mita M, Lane A, Moseley J, Dedieu JF, Stash D,
      Zhi X, Mazuir F, Mita A. Phase I trial of cabazitaxel plus cisplatin in patients with advanced solid tumors; 2012 Jan. (Journal Clinical Oncology 30:5s ASCO Genitourinary Symposium 2012). Sarantopoulos J, Hoering A, Synold T, Mahalingam D, Wang D, Lenz HJ , O?Rourke P, Sexton R, Van Veldhuizen P, Mita M , Wong L, Mita A, El-Khoueiry A, Chung V, Gandara D , Tejwani S, Takebe N, Takimoto CH, Ivy P , Kurzrock R. Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) in Patients with Advanced Malignancies and Varying Levels of Liver Dysfunction: S0711,a SWOG Early Therapeutics Committee Study; 2012 Jan. (Journal Clinical Oncology 30:15s ASCO 2012). Mahalingam D, Mita M, Sarantopoulos J, Woods L, Mita A, Curiel T, Argiris A, Nawrocki S,
      Carew J, Giles F.
      . Inhibition of Autophagy: Phase 1 Safety, Tolerability, and Pharmacokinetic Analysis of Hydroxychloroquine in Combination with the HDAC inhibitor Vorinostat in Patients with Advanced Solid Tumors; 2012 Jan. (Journal Clinical Oncology 30:15s ASCO 2012). Ramanathan R, Chadha M , Sarantopoulos J, Northfelt D, Weiss G, Mita M, Barnhart K,
      Whisnant J, Leuschner C, Curtis K.
      . A Phase I study of EP100, a Luteinizing Hormone Releasing Hormone (LHRH) ligand conjugated to a synthetic cytolytic peptide in patients with advanced refractory LHRH- receptor (R)-expressing solid tumors; 2012 Jan. (Journal Clinical Oncology 30:15s). Mita AC, Sundaram S, Sarantopoulos J, Mita M, Lane A, Moseley J, Mahalingam D, Tan Jr. B, Dedieu JF, Stash D, Zhi X, Mazuir F, Lockhart A.
      . Cabazitaxel plus cisplatin co-administration and drug-interaction study in patients with advanced solid tumors; 2012 Jan. (Journal Clinical Oncology 30:15s ASCO 2012). Hutson T, Dang L, Lauer R, Starodub A, Hauke R, Galsky M, Bylow K, Logan T, Cowey C, Bibby D, Kremmidiotis G, Doolin E, Lavranos T, Sonpavde G, Hahn N, Sweeney C, Sarantopoulos J.
      . Phase I results of a phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients previously treated with VEGFR tyrosine kinase inhibitors. (Hoosier Oncology Group); 2012 Jan. (Journal Clinical Oncology 30:15s ASCO 2012). Sarantopoulos J, Goel S, Chung V, Mahalingam D, Sankhala K, Rivera-Flannery M, Rance C,Olivo M, Tan A. Phase I Study to Assess the Safety and Pharmacokinetics of eribulin mesylate (E7389) in Patients With Advanced Cancer and Impaired Renal Function; 2012 Jan. (Submitted TPS ASCO 2012). Gurtler J, Sarantopoulos J, Hsueh C, Wade J, Lockhart A, Pandya S, Quinn D, Hwang J,
      Shine U, Wack C, Yin J, Rixe O.
      . Safety and pharmacokinetic study of cabazitaxel in advanced solid tumor patients with varying degrees of hepatic impairment; 2012 Jan. (Submitted TPS ASCO 2012). Mita A, Senzer N, Vemulapalli S, Sarantopoulos J, Mahalingam D, Mita M, Hart J, Gallegos N, Anderson G, Charles J, Kousba A, Rogers J, Nemunaitis J. ATI-1123, a novel human albumin-stabilized docetaxel liposomal formulation: final results of a phase I study in patients with advanced solid malignancies; 2011 Jan. (Proc AACR/NCI/EORTC International Conference of Molecular Targets and Cancer Therapeutics 2011). Hutson T, Sarantopoulos J, Logan T, Sonpavde G, Galsky M, Sweeney C, Bibby B, Kremmidiotis G, Doolin E, Hahn N.
      . Hoosier Oncology Group.: Phase I/II study of BNC105P in combination with everolimus or following everolimus for progressive metastatic renal cell carcinoma following prior tyrosine kinase inhibitors; 2011 Jan. (Journal Clinical Oncology 29:15s ASCO 2011). Sankhala K, Tolcher A, Mita M, Gordon M, Rosen L,Papadopoulos K, Patnaik A, Drengler
      R, Mita A, Sarantopoulos J, Bristow R,Fine G, Choy G, Azab M. Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: Final results from a 100-patient, 5-arm phase Ib trial in combination with five standard of care anticancer regimens; 2011 Jan. (Journal Clinical Oncology 29:15s ASCO 2011). Saif MW, Lichinitser M, Gordon M, Tan B, Scheulen M, Pandya NB, Sarantopoulos J,
      Rinehart J, Verschraegen C, Lenz H, Zergebel C, Saito K. A phase I study evaluating the pharmacokinetics of components of S-1 in pts with varying degrees of renal function; 2011 Jan. (Journal Clinical Oncology 29:15s ASCO 2011). Mita M, Mita A, Moseley J, Poon J, Small K, Jou Y, Kirschmeier P, Zhang D, Statkevich P,
      Sankhala K, Sarantopoulos J, Cleary J, Chirieac L, Rodig S, Bannerji R, Shapiro G. A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients with advanced malignancies: Final results; 2011 Jan. (Journal Clinical Oncology 29:15s ASCO 2011). Kauh J, Shapiro G, Cohen RB, Clark J, Harvey RD, Cleary J, Mahalingam D, Kuan S, McDonald A, Berger A, Dezube B, Sarantopoulos J.
      . MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients with advanced solid tumors: Phase I study of multiple treatment schedules; 2011 Jan. (Journal Clinical Oncology 29:15s ASCO 2011). Mita A, Mita M, Rocha C, Bradley C, Sarantopoulos J, O'Rourke P, Gadgeel S, Wozniak A,Heath E. A phase IB trial of iniparib (BSI-201) in combination with carboplatin /paclitaxel in patients with non-small cell lung cancer; 2011 Jan. (Journal Clinical Oncolology 29:15s ASCO 2011). Vemulapalli S, Mita A, Gallegos N, Anderson G, Charles J, Rogers J, Kousba A, Sankhala
      K, Sarantopoulos J, Nemunaitis J.
      . Phase I study of ATI-1123, a novel human serum albumin-stabilized docetaxel liposomal formulation, in patients with advanced solid malignancies; 2011 Jan. (Journal Clinical Oncology 29:15s ASCO 2011). Brenner A, Cohen Y, Giles F, Borden E, Breitbart E, Bangio L, Sher N, Triozzi P. A phase I trial of VB-111, a tissue- and condition-specific dual action vascular disruptive and antiangiogenic agent, for treatment of patients with advanced metastatic cancer; 2011 Jan. (Journal Clinical Oncology 29:15s ASCO 2011). Tawbi H, Rodon J, Dummer R, Thomas A, Granvil C, Shou Y, Dey J, Mita M, Amakye D, Mita A. Phase I study of LDE225 in advanced solid tumors: Updated analysis of safety, preliminary efficacy, and pharmacokinetic-pharmacodynamic correlation; 2011 Jan. (Journal Clinical Oncology 29:15s ASCO 2011). Sarantopoulos J, Lenz H, LoRusso P, Shibata S,Kummar S, Mulkerin D, Ramanathan R,Mita M, O'Rourke P, Remick S, Goel S, Gutierrez M, Ramalingam S, Murgo A, Davies A,Mani S, Boni J, Shapiro M, Ivy SP, Takimoto C.
      . National Cancer Institute Organ Dysfunction Working Group.: Phase I pharmacokinetic study of temsirolimus (CCI-779) in patients with advanced malignancies and normal and impaired liver function: An NCI Organ Dysfunction Working Group (ODWG) study; 2011 Jan. (Journal Clinical Oncology 29:15s ASCO 2011). Mahalingam D, Sarantopoulos J, Gordon M, Pandya N, Tan B, Mita A, Zergebel C, Saito K,
      Takimoto C, Saif MW. Phase I study evaluating the pharmacokinetics (PK) of components of S-1 in patients with impaired hepatic function; 2011 Jan. (Journal Clinical Oncology 29:15s ASCO 2011). Falchook G, Sarantopoulos J, Kurrock R, Mita A, Fu S, Mita M, Zhou X, Milch C, Jung J,
      Venkatakrishnan K, Rosen L.
      . Phase 1 relative bioavailability study of a prototype oral solution formulation of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in reference to a powder-in-capsule formulation in patients with advanced solid tumors; 2011 Jan. (Proc AACR/NCI/EORTC International Conference of Molecular Targets and Cancer). Wen P, Drappatz J, Brenner A, Mikkelsen T, Schiff D, Rosenfeld S, Groves M, Shen Y,
      Wang X, Shing M, Lawrence B, Castaigne JP, Gabrail N, Sarantopoulos J, Kurzrock R.
      . GRN1005 Phase I Studies : Final Results; 2011 Jan. (Proc AACR/NCI/EORTC International Conference of Molecular Targets and Cancer Therapeutics 2). Mahalingam D, Mita A, Kousba A, Vemulapalli S, Gallegos N, Anderson G, Charles J, Rogers J, Sarantopoulos J, Mita M, Senzer N, Nemunaitis J. Phase I pharmacokintetic Assessments of ATI-1123, a novel human serum albumin-stabilized nanoparticle docetaxel liposomal formulation, in patients with advanced solid malignancies; 2011 Jan. (Proc AACR/ NCI/ EORTC International Conference of Molecular Targets and Cancer Therapeutics 2011). Mita M, Wang Y, Sarantopoulos J, Vemulapalli S, George B, Mita A, Coffey M, Gill G,
      Mahalingam D. A Study of Reolysin in combination with Gemcitabine in patients with advanced pancreatic adenocarcinoma; 2011 Jan. (Proc AACR/NCI/EORTC International Conference of Molecular Targets and Cancer Therapeutics 20). McDonald A, Burke K, Thomas M, Berger A, Smith P, Tirrell S, Blakemore S, Mulligan
      G, Pickard M, Fleming M, Kauh J, Sarantopoulos J, Dezube B, Stringer B. Development and implementation of immunohistochemistry based pharmacodynamic biomarkers demonstrate NAE pathway inhibition in MLN4924 solid tumor clinical trials; 2011 Jan. (Proc AACR/NCI/EORTC International Conference of Molecular Targets and Cancer Therapeutics 20). Mita A, Mita M, Sarantopoulos J, Martin J, Kueber J, McGonigle S, Matijevic M, Mistry B,
      Ferrada J, Sachdev P, Stephenson J. Phase I study of the safety, pharmacokinetics, and pharmacodynamics of the poly(ADP-ribose) polymerase (PARP) inhibitor E7016 in combination with temozolomide in patients with advanced solid tumors; 2011 Jan. (Proc AACR/ NCI/ EORTC International Conference of Molecular Targets and Cancer Therapeutics 2011). Mahalingam D, Beeram, M, Rodon J, Sankhala K, Mita A, Benjamin D, Michalek J, Tolcher A, Wright J, Sarantopoulos J. Phase II study evaluating the efficacy, safety and Pharmacodynamic correlative study of dual anti-angiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma; 2010 Nov. (EORTC-NCI-AACR-Symposium on Molecular Targets and Cancer Therapeutics). Venkatakrishnan K, Ramanathan R, Sarantopoulos J, Mulkerin D, Shibata S, Hamilton A,
      Dowlati A, Mani S, Rudek M, Ivy P, Takimoto C, Neuwirth R, Parasuraman S, LoRusso P. Pharmacokinetics and safety of Bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: Results of the Phase 1 National Cancer Institute Organ Dysfunction Working Group Study NCI 6432. Oral Presentation; 2010 Nov. (Blood (ASH Annual Meeting Abstracts),; vol. 116). Sarantopoulos J, Rosen LS, Chap L, Mita A, Papadopoulos K, Mita M, Wood L, Nichols S, Tolcher A, Tamby JF, Patnaik A. Phase I dose escalation and pharmacokinetic study of Intravenous aflibercept (VEGF Trap) plus weekly gemcitabine and daily erlotinib in patients with advanced solid tumors: preliminary results; 2010 Jul. (12th World Congress on Gastrointestinal Cancer 2010). Montgomery RB, Morris M, Ryan CJ, Stickney D, Frincke J, Reading C, Sarantopoulos J, Scher HI. HE3235, a synthetic adrenal hormone disease-modifying agent, in castrate resistant prostate cancer: Results of phase I/II clinical trial; 2010 Jun. (Journal Clincal Oncology ASCO 2010). Drappatz J, Brenner A, Rosenfeld S, Groves, Mikkelsen T, Schiff D, Sarantopoulos J, Wong E, Wen PY, Castaigne JP. ANG 1005: Results of phase I study in patients with recurrent malignant glioma; 2010 Jun. (Journal Clincal Oncology ASCO 2010). Puzanov I, Sarantopoulos J, Gilbert J, Mahalingam D, Chap L, Deng H, Zhu M, McCaffery L, Friberg G, Rosen LS. Safety and pharmacokinetics of AMG 479 in conmbinationiwth Erlotinib or Sorafenib in patients with advanced solid tumors; 2010 Jun. (Journal Clincal Oncology ASCO 2010). Egorin M, Kummar S, Sarantopoulos J, Shibata S, LoRusso P, Yerk M, Lin Y, Ivy SP, Belani C, Ramalingam S. Phase I study of Vorinostat for patients with advanced solid tumors and hepatic dysfunction: An NCI organ dysfunction working group study; 2010 Jun. (Journal Clincal Oncology ASCO 2010). Shibata S, Longmate J, Chung V, Lenz HJ, Kummar S, Sarantopoulos J, Harrison M, Synold T, Ivy SP, Newman E. A phase I and pharmacokinetic single agent study of Pazopanib in patients with advanced malignancies and varying degrees of liver dysfunction in patients with advanced solid tumors and brain metastases; 2010 Jun. (Journal Clincal Oncology ASCO 2010). Sarantopoulos J, Gabrail N, Moulder S, Brenner A, Smith C, Bouchard D, Elian K, Lawrence B, Castaigne JP, Kurzrock R. ANG 1005: Results of a Phase I study in patients with advanced solid tumors and brain metastases; 2010 Jun. (Journal Clincal Oncology ASCO 2010). Kahn D, Mita A, George B, Sankhala K, Mahalingam D, Kelly K, Karnad A, Sarantopoulos J, Mita M. Mammalian target of rapamycin (mTOR)-induced pneumonitis: Single-institution experience and treatment; 2010 Jun. (Journal Clincal Oncology ASCO 2010). Mahalingam D, Beeram M, Rodon J, Sankhala K, Mita A, Benjamin D, Michalek J, Tolcher A, Wright J, Sarantopoulos J. Phase II study evaluating the efficacy, safety and Pharmacodynamic correlative study of dual anti-angiogenic inhibitionusing bevacizumab in combination with sorafenib in patients with advanced malignant melanoma; 2010 Jun. (Journal Clincal Oncology ASCO 2010). George S, Beeram M, Ricart A, Mita A, Brenner A, Ketchum K, Egorin M, Tolcher A, Zwiebel J, Sarantopoulos J. A phase II pharmacokinetic and biologic correlative study of Vorinostat (suberoylanilide hydroxamic acid or SAHA) in advanced renal cell carcinoma patients; 2010 Jan. (ASCO GU 2010). Seiwart T, Swann S, Kurz H, Bonate P, McCallum S, Sarantopoulos J. A phase II study of the efficacy and safety of foretinib in patients with recurrent or metastatic squamous cell cancer of the head and neck; 2009 Nov. (Proc AACR/EORTC/NCI International conference of Molecular Targets and Cancer Therapeutics 2009). Kuzrock R, Gabrail N, Moulder S, Noles C, Smith C, Guo Z, Bouchard D, Churchill W, Bento P, Neale A, Castaigne JP, Sarantopoulos J. ANG1005: Results of Phase I study in patients with advanced solid tumors and metastatic brain cancer; 2009 Nov. (Proc AACR/EORTC/NCI International conference of Molecular Targets and Cancer Therapeutics 2009). Kauh JS, Cohen R, Clarke JW, Harvey R, Mulligan G, Benkatakrishnan K, Berger A, smith PG, Petruzelli L, Sarantopoulos J. Pharmacodynamic effects of MLN4924, a novel NAE inhibitor, on blood and skin; 2009 Jun. (Journal Clinic Oncology ASCO 2009). McCaffery I, Tolcher AW, Puzanov I, Sarantopoulos J, Rosen L, Deng H, Paweletz K, Friberg G. Analysis of biomarkers during early phase clinical development of AMG 479 an investigational fully human monoclonal antibody antagonist of type 1 insulin-like growth factor receptor (IGF-1R); 2009 Jun. (Journal Clinical Oncology ASCO 2009). Kurzrock R, Wheler J, Gabrail N, Brenner A, Guo Z, Bouchard D, Bento P, Churchil W, Fitsialos D, Castaigne JP, Sarantopoulos J. ANG1005, a conjugate of Angiopep-2 and paclitaxel: Development of a new chemical entity for the treatment of advanced solid tumors and brain metastases; 2009 Apr. (Proc AACR 2009; vol. #3782). Rothenberg ML, Tolcher AW, Sarantopoulos J, Rodon J, Friberg G, Deng H, McCaffery I, Hwang I, Puzanov I. AMG 479 monotherapy to treat patients with advanced GI carcinoid tumors: A subset analysis from the first-in-human study; 2009 Jan. (Proc ASCO GI 2009). Kurzrock R, Fu S, Mita AC, Guo Allison C, Bouchard D, Elian KM, Neale A, Castaigne JP, Sarantopoulos J. ANG 1005, an Angiopep-2/paclitaxel conjugate; the first clinical trial in patients with advanced cancer and brain metastases: preliminary safety and tolerability data; 2008 Oct. (Proc EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2008). Giles F, O`Brien S, Vey N, Rizzieri D, Sarantopoulos J, Prebet T, Ravandi F, Faderl S, Charbonnier A, Jacobsen T, Nilsson B, Staudacher K, Kantarjian H. A phase I with CP-4055 in patients with haematologic malignancies; 2008 Jul. (13th Congress European Hematology Association 2008). Sarantopoulos J, Mita A, Mulay M, Romero O, Lu J, Capilla F, Chen L, Hwang Y, Friberg G, Rosen LS. A Phase IB study of AMG 479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumb or gemcitabine tumors; 2008 Jun. (Proc ASCO 2008). Dueland S, Aamdal S, Lundgren L, Wagenius G, Sarantopoulos J, Kirkwood J, Stierner U, Gaullier J, Rasch W. A multicentre dose finding, phase II study of CP-4055 in combination with sorafenib in patients with metastatic melanoma; 2008 Jun. (Proc ASCO 2008). Soefje SA, Sarantopoulos J, Sankhala K, Mita A, Mahany JJ, Carmona T, Coffey M, Gill GM, Mettinger K, Mita M. A Phase II study of intravenous reolysin ( Wild-type reovirus) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung; 2008 Jun. (Proc ASCO 2008). Reid TR, Takimoto CH, Verschraegen CF, Sarantopoulos J, Cheung W, Allen-Freda E, Li J, Xu Y, Ko J, Johri A. Evaluaton of safety, tolerability and pharmacokinetics of patupilone in patients with advanced solid tumors and varying degrees of hepatic function; 2008 Jun. (Proc ASCO 2008). Patnaik A, Pipas M, Rosen LS, Wood L, Phipps K, Mulay M, Garay C, Kroc M, Sarantopoulos J. A Phase I dose escalation and pharmacokinetic study of intravenous aflibercept (VEGF Trap) plus weekly gemcitabine in patients with advanced solid tumors; 2008 Jun. (Proc ASCO 2008). Batist G, Tolcher A W, Sarantopoulos J, Sankhala K, Fontanilla J, Lu, Baio Choy G, Deitcher S. A Phase I and pharmacokinetic study of vinorelbine liposomes injection in patients with advanced solid tumors, non Hodgkin`s lymphoma, and Hodgkin`s disease; 2007 Oct. (Proc AACR/EORTC/NCI International conference of Molecular Targets and Cancer Therapeutics 2007). Sankhala K, Mita A, Ricart A, Mita M, Lin C, Wood L, Sarantopoulos J, Takimoto C, Patnaik A, Qin A, Zildjian S, Tolcher A.:. A phase I and pharmacokinetic study of a CanAg-targeted immunoconjugate, HuC242-DM4, in patients with CanAg-expressing solid tumors; 2007 Oct. (Proc AACR/EORTC/NCI International conference of Molecular Targets and Cancer Therapeutics 2007; vol. B70). Takimoto CH, Chu Q, Yen Y, O`Rourke P, Cooper J, Padro S, Tolcher AW, Patnaik A, Papadopoulos K, Beeram M, Ricart A, Lin C, Mita A, Calvo E, Espinoza-Delgado I, Zwiebel J, Sarantopoulos J. A phase I pharmacokinetic and pharmacodynamic study of GT12040, a novel ribonucleotide inhibitor in combination with gemcitabine in adult patients with advanced solid tumors; 2007 Oct. (Proc AACR/EORTC/NCI International conference of Molecular Targets and Cancer Therapeutics 2007). Takimoto CH, Ricart A, Mita MM, Mita AC, Chu Q, Tolcher AW, Sarantopoulos J, Rowinsky EK. Phase I evaluation of a 24-h infusion of TAS-106 every 3 weeks in patients with solid tumors; 2007 Jun. (Proc ASCO 2007; vol. 18S, no. 100s). Ross RW, Stein M, Sarantopoulos J, Eisenberg T, Logan S, Srinivas S, Rosenberg J,
      Vaishampayan U
      . A Phase II study of the c-Met RTK inhibitor XL880 in patients with papillary renal cell carcinoma; 2007 Jun. (Proc ASCO 2007; vol. 18s, no. 658s). Mita M, Ricart A, Mita AC, Patnaik A, Sarantopoulos J, Sankhala K, Fram RJ, Qin A, Watermill, Tolcher AW. A Phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors; 2007 Jun. (Proc ASCO 2007; vol. 18S, no. 133s). Papadopoulos KP, Setlik R, Sarantopoulos J, Fracasso P, Wong A, Duchin K, Martinez-Bonguli D, Tolcher AW. Phase I pharmacokinetic interaction and safety study of DN-101/docetaxel in patients with advanced solid tumors; 2007 Apr. (Proc AACR 2007). Tolcher A, Ricart A, Rodon J, Patnaik A, Mita AC, Mita MM, Sarantopoulos J, Zildjian, Watermill J, Fram RJ. A Phase I study of huC242DM4 to assess the safety and pharmacokinetics of huC242-DM4 administered as a single intravenous infusion once every three weeks to subjects with solid tumors; 2006 Nov. (Proc EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2006; vol. 4, no. 12). Sarantopoulos J, Tolcher A, Wong A, Goel S, Beeram M, Lam G, Desai K, Woody K, Mani S, Papadopoulos K. Banoxantrone (AQ4N), tissue CYP 450 targeted prodrug: The results of a Phase I study using an accelerated dose escalation; 2006 Jun. (Proc ASCO 2006; vol. 24, no. 18S). George BJ, Ricart A, Calvo E, Chu Q, Sarantopoulos J, Greene D, Nathan FE, Petrone ME, Tolcher, Papadopoulos KP
      . Phase I pharmacokinetic/ food effect and safety study of satraplatin in patients with advanced solid tumors; 2006 Jun. (Proc ASCO 2006). Beeram M, Saif MW, Sarantopoulos J, Schwartz G, Patnaik A, Tolcher AW, Mehdi F, Feit
      K, Takimoto CH
      . A Phase I, Pharmacokinetic and Pharmacodynamic study of the combination of an oral antimicrotubular agent, DJ-927, and Capecitabine in Patients with advanced cancers; 2006 Jun. (Proc ASCO 2006). Mays TA, Sarantopoulos J, Tolcher A, Lowy I, Preston G, Levy E, Oslund M, Manchen E, Kelly A, Stadler. MDX-070, a human anti-PSMA antibody, administered as either a single dose or as multiple doeses to patients with hormone-refractory prostate cancer; 2006 Jun. (Proc ASCO 2006; vol. 24, no. 18S). Mita AC, Papadopoulos K, Mita MM, Ricart A, Sarantopoulos J, Berg k, Urtiz B, Levy E, Lowy I, Tolcher A. A Phase I, pharmacokinetic and pharmacodynamic study of MDX-214, a novel immune-mediated mechanism agent targeting the epithelial growth factor receptor, in patients with advanced solid tumors; 2006 Jun. (Proc ASCO 2006; vol. 24, no. 18S). Setlik RF, Preston G, Jones CB, Sarantopoulos J, Dufresne T, Petrone ME, Nathan FE, Green D, Anthony T, Takimoto CH. Phase I study of the effects of hepatic impairment on the pharmacokinetic and safety of satraplatin in patients with refractory non-hematologic cancer; 2006 Jun. (Proc ASCO 2006; vol. 24, no. 18S). Ricart A, Cooney M, Sarantopoulos J, Brell J, Locke KW, Gammans RE, Medina G, Zambito A, Tolcher A, Remick SC. A phase I pharmacokinetic and pharmacodynamic study of MN-029, a novel vascular disrupting agent, in patients with advanced solid tumors; 2006 Jun. (Proc ASCO 2006; vol. 24, no. 18S). Preston G, Calvo E, Papadopoulos K, Patnaik A, Mita AC, Sarantopoulos J, Mita MM, O`Rourke P, Takimoto CH, Tolcher A. Multi-targeted inhibition of the epidermal growth factor (EGFR) and vascular endothelial growth factor receptor (VEGFR) pathways: A Phase I study of cetuximab, erlotinib, and bevacizumab in patients with solid tumors; 2006 Jun. (Proc ASCO 2006; vol. 24, no. 18S). Ricart A, Sarantopoulos J, Calvo E, Chu Q, Tolcher AW, Greene D, Nathan FE, Petrone
      ME, Dufresne T, Papadopoulos KP
      . A Phase I Pharmacokinetic (PK) / Food Effect and Safety Study of Satraplatin in Patients (pts) with Refractory Solid Malignancies; 2006 Jan. (Proc ASCO Prostate 2006). Sarantopoulos J, Wakelee H, Mita MM, Fitzgerald A, Hill M, Fox NL, Howard T, Ulrich S, Tolcher A, Sikic B. HGS-ETR2-ST02: A Phase I Clinical Trial of HGS-ETR2, a Fully-Human Activating Monoclonal Antibody to TRAIL-R2, In Patients with Advanced Solid Tumors; 2005 Nov. (Proc AACR/EORTC/NCI International conference of Molecular Targets and Cancer Therapeutics 2005; vol. C21). Beeram M, Saif MW, Sarantopoulos J, Schwartz G, Patnaik A, Tolcher A, Cheverton M, Kimura M, Danna M, Takimoto CH. A Phase I, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of the Combination of an Oral Antimicrotubular agent, DJ-927 (D), and Capecitabine (C) In Patients (pts) with Advanced Solid Tumors; 2005 Jun. (Proc ASCO 2005; vol. 23, no. 16S).

      Journal Article

      Sarantopoulos J. Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer Target Oncology 2016 Jun;11(3):317-323. Sarantopoulos J. Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors Cancer 2016 May;. Sarantopoulos J. Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors Drugs R D 2016 Mar;(1):45-52. Sarantopoulos J. Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors Clin Cancer Res 2016 Feb;22(4):847-857. Sarantopoulos J. Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function Cancer Chemother Pharmacol 2015 Nov;76(5):1051-1061. Sarantopoulos J. A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma Clin Cancer Res 2015 Aug;21(15):3420-3427. Sarantopoulos J. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors Int J Clin Pharmacol Ther 2015 Jul;53(7):563-572. Sarantopoulos J. Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel Cancer Chemother Pharmacol 2014 Dec;:1113-1124. Sarantopoulos J. Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors Invest New Drugs 2014 Dec;32(6):1236--1245. Sarantopoulos J. Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors Cancer Chemother Pharmacol 2014 Dec;74(6):1241-1250. Sarantopoulos J. Predicting success in regulatory approval from Phase I results Cancer Chemother Pharmacol 2014 Nov;74(5):1099--103. Sarantopoulos J. Clinical outcomes and survival of advanced renal cancer patients in phase I clinical trials Clin Genitourin Cancer 2014 Oct;12(5):359--365. Sarantopoulos J. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors Autophagy 2014 Aug;10(8):1403--1414. Curtis KK, Sarantopoulos J, Northfelt DW, Weiss GJ, Barnhart KM, Whisnant JK, Leuschner C, Alila H, Borad MJ, Ramanathan RK. Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors. doi: 10.1007/s00280-014-2424-x. Epub 2014 Mar 8 Cancer Chemother Pharmacol 2014 May;73(5):931-941. Patel SR, Karnad AB, Ketchum NS, Pollock BH, Sarantopoulos J, Weitman S, Mahalingam D. Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials J Gastrointest Oncol 2014 Apr;5(2):99-103. Rodon J1, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. doi: 10.1158/1078-0432.CCR-13-1710. Epub 2014 Feb 12 Clin Cancer Res 2014 Apr;20(7):1900-1909. Malik L, Parsons HM, Mahalingam D, Ehler B, Goros M, Brenner AJ, Sarantopoulos J. Clinical outcomes and survival of advanced renal cancer patients in phase I clinical trials Clin Genitourin Cancer 2014 Feb;12(5):359-365. Harland S1, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI, Sarantopoulos J. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy Eur J Cancer 2013 Nov;49(17):3648-3657. Shibata SI, Chung V, Synold TW, Longmate JA, Suttle AB, Ottesen LH, Lenz HJ, Kummar S, Harvey RD, Hamilton AL, O`Neil BH, Sarantopoulos J, LoRusso P, Rudek MA, Dowlati A, Mulkerin DL, Belani CP, Gandhi L, Lau SC, Ivy SP, Newman EM.
      . Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study Clin Cancer Res 2013 Jul;19(13):3631-3639. Mita M, Gordon M, Rejeb N, Gianella-Borradori A, Jego V, Mita A, Sarantopoulos J, Sankhala K, Mendelson D. A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors Target Oncol., [Epub ahead of print] 2013 Jul;. Seiwert T, Sarantopoulos J, Kallender H, McCallum S, Keer HN, Blumenschein G. Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck Invest New Drugs 2013 Apr;31(2):417-424. Mita MM, Poplin E, Britten CD, Tap WD, Rubin EH, Scott BB, Berk L, Rivera VM, Loewy JW, Dodion P, Haluska F, Sarantopoulos J, Mita A, Tolcher A. Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma Ann Oncol 2013 Apr;24(4):1104-1111. Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD, Mikkelsen T, Rosenfeld S, Sarantopoulos J, Meyers CA, Fielding RM, Elian K, Wang X, Lawrence B, Shing M, Kelsey S, Castaigne JP, Wen PY.
      . Phase I study of GRN1005 in recurrent malignant glioma Clin Cancer Res 2013 Mar;19(6):1567-1576. Nemunaitis J, Mita A, Stephenson J, Mita MM, Sarantopoulos J, Padmanabhan-Iyer S, Nanda N, Gleich L, Benichou AC, Craig A.
      . Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors Cancer Chemother Pharmacol 2013 Jan;71(1):35-41. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS; COU-AA-301 Investigators, Sarantopoulos J,. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 2012 Oct;13(10):983-992. Rosen LS, Puzanov I, Friberg G, Chan E, Hwang YC, Deng H, Gilbert J, Mahalingam D, McCaffery I, Michael SA, Mita AC, Mita MM, Mulay M, Shubhakar P, Zhu M, Sarantopoulos J. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors Clin Cancer Res 2012 Jun;18(12):3414-3427. LoRusso PM, Venkatakrishnan K, Ramanathan RK, Sarantopoulos J, Mulkerin D, Shibata SI, Hamilton A, Dowlati A, Mani S, Rudek MA, Takimoto CH, Neuwirth R, Esseltine DL, Ivy P. Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432 Clin Cancer Res 2012 May;18(10):2954-2963. Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, Brenner A, Sankhala K, Mita A, Elian K, Bouchard D, Sarantopoulos J. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors Mol Cancer Ther 2012 Feb;11(2):308-316. Saif MW, Sarantopoulos J, Patnaik A, Tolcher AW, Takimoto C, Beeram M. Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors Cancer Chemother Pharmacol 2011 Dec;68(6):1565-1573. Swords R, Kelly K, Carew J, Nawrocki S, Mahalingam D, Sarantopoulos J, Bearss D, Giles F.
      . The Pim kinases: new targets for drug development Curr Drug Targets 2011 Dec;12(14):2059-2066. Leal TB, Remick SC, Takimoto CH, Ramanathan RK, Davies A, Egorin MJ, Hamilton A, LoRusso PA, Shibata S, Lenz HJ, Mier J, Sarantopoulos J, Mani S, Wright JJ, Ivy SP, Neuwirth R, von Moltke L, Venkatakrishnan K, Mulkerin D.
      . Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study Cancer Chemother Pharmacol 2011 Dec;68(6):1439-1447. Ricart AD, Ashton EA, Cooney MM, Sarantopoulos J, Brell JM, Feldman MA, Ruby KE, Matsuda K, Munsey MS, Medina G, Zambito A, Tolcher AW, Remick SC. A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors Cancer Chemother Pharmacol 2011 Oct;68(4):959-970. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators, Sarantopoulos J. Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 2011 May;364(21):1995-2005. Ramalingam SS, Kummar S, Sarantopoulos J, Shibata S, LoRusso P, Yerk M, Holleran J, Lin Y, Beumer JH, Harvey RD, Ivy SP, Belani CP, Egorin MJ. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study J Clin Oncol 2010 Oct;28(29):4507-4512. Mita AC, Takimoto CH, Mita M, Tolcher A, Sankhala K, Sarantopoulos J, Valdivieso M, Wood L, Rasmussen E, Sun YN, Zhong ZD, Bass MB, Le N, LoRusso P. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors Clin Cancer Res 2010 Jun;16(11):3044-3056. George S, Brenner A, Sarantopoulos J, Bukowski RM. RANK ligand: effects of inhibition Curr Oncol Rep 2010 Mar;12(2):80-86. Sankhala KK, Pandya DM, Sarantopoulos J, Soefje SA, Giles FJ, Chawla SP. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant Expert Opin Drug Metab Toxicol 2009 Dec;5(12):1607-1614. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, Murphy B, Roth B, McCaffery I, Gorski KS, Kaiser B, Zhu M, Deng H, Friberg G, Puzanov I. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1 J Clin Oncol 2009 Dec;27(34):5800-5807. Mita M, Mita A, Sarantopoulos J, Takimoto CH, Rowinsky EK, Romero O, Angiuli P, Allievi C, Eisenfeld A, Verschraegen CF
      . Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies Cancer Chemother Pharmacol 2009 Jul;64(2):287-295. Ricart AD, Sarantopoulos J, Calvo E, Chu QS, Greene D, Nathan FE, Petrone ME, Tolcher AW, Papadopoulos KP. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study Clin Cancer Res 2009 Jun;15(11):3866-3871. Lin CC, Calvo E, Papadopoulos KP, Patnaik A, Sarantopoulos J, Mita AC, Preston GG, Mita MM, Rodon J, Mays T, Yeh IT, O`Rourke P, Takimoto CH, Dancey JE, Chen H, Tolcher AW. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors Cancer Chemother Pharmacol 2009 May;63(6):1065-1071. Papadopoulos KP, Goel S, Beeram M, Wong A, Desai K, Haigentz M, Milian ML, Mani S, Tolcher A, Lalani AS, Sarantopoulos J. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies Clin Cancer Res 2008 Nov;14(21):7110-7115. Czubryt MP, Russell JC, Sarantopoulos J, Gilchrist JS, Pierce GN. Age- and sex-related differences in nuclear lipid content and nucleoside triphosphatase activity in the JCR:LA-cp corpulent rat Mol Cell Biochem 1997 Nov;176(1-2):327-335. Czubryt MP, Russell JC, Sarantopoulos J, Pierce GN. Nuclear cholesterol content and nucleoside triphosphatase activity are altered in the JCR:LA-cp corpulent rat J Cell Biochem 1996 Dec;63(3):349-357.

  • Clinical

    Board Certifications

    • American Board of Internal Medicine/Medical Oncology